Emcure Pharmaceuticals' Q3 FY 2025-26 Quarterly Results
- 05 Feb 2026
Result Summary
- Emcure Pharmaceuticals Ltd reported a 4.1% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 20.3%.
- Its expenses for the quarter were up by 4.2% QoQ and 15.9% YoY.
- The net profit decreased 8.0% QoQ and increased 48.2% YoY.
- The earnings per share (EPS) of Emcure Pharmaceuticals Ltd stood at 12.16 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 2365.33 | 2272.94 | 1966.53 | 4.1% | 20.3% |
Total Expenses | 2013.39 | 1931.52 | 1736.61 | 4.2% | 15.9% |
Profit Before Tax | 313.79 | 341.42 | 229.92 | -8.1% | 36.5% |
Tax | 82.42 | 90.05 | 73.83 | -8.5% | 11.6% |
Profit After Tax | 231.37 | 251.37 | 156.09 | -8.0% | 48.2% |
Earnings Per Share | 12.16 | 12.85 | 8.12 | -5.4% | 49.8% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Emcure Pharmaceuticals Ltd is a prominent player in the pharmaceutical industry, known for its extensive range of healthcare products. The company specializes in the development, manufacturing, and marketing of a diverse array of pharmaceutical products, including formulations, active pharmaceutical ingredients (APIs), and biotechnology products. Emcure has established a strong presence in both domestic and international markets, with a focus on delivering high-quality healthcare solutions. While specific recent developments are not provided, it is common for companies in this sector to engage in activities such as launching new products, expanding production capabilities, and entering new markets to enhance their market position.
Revenue
For the third quarter of fiscal year 2026 (Q3FY26), Emcure Pharmaceuticals Ltd reported a total income of ₹2365.33 crores. This represents a quarter-over-quarter (QoQ) increase of 4.1% from the previous quarter (Q2FY26), where the total income was ₹2272.94 crores. On a year-over-year (YoY) basis, the total income grew by 20.3% compared to the same quarter in the previous fiscal year (Q3FY25), which had a total income of ₹1966.53 crores. The consistent growth in revenue reflects the company's ability to maintain a strong market presence and possibly expand its product offerings.
Profitability
Emcure Pharmaceuticals Ltd reported a profit before tax of ₹313.79 crores in Q3FY26, reflecting a decrease of 8.1% from the previous quarter (Q2FY26) where the profit before tax was ₹341.42 crores. However, on a YoY basis, there was a significant increase of 36.5% from Q3FY25, which recorded a profit before tax of ₹229.92 crores. The profit after tax for Q3FY26 was ₹231.37 crores, marking an 8.0% decline from Q2FY26, but a notable increase of 48.2% compared to Q3FY25. The earnings per share (EPS) for Q3FY26 was ₹12.16, down 5.4% from the previous quarter, but up 49.8% from the same period last year. These figures indicate shifts in profitability across quarters and years.
Operating Metrics
Total expenses for Emcure Pharmaceuticals Ltd in Q3FY26 amounted to ₹2013.39 crores, showing a 4.2% increase from Q2FY26, which had total expenses of ₹1931.52 crores. Compared to Q3FY25, total expenses increased by 15.9%, from ₹1736.61 crores. The tax expense for Q3FY26 was ₹82.42 crores, representing a decrease of 8.5% from Q2FY26 and an increase of 11.6% from Q3FY25. These operating metrics highlight changes in the company's cost structure and tax obligations over the analyzed periods.